References
1. Amer, S. , 2007. Gonadotrophin induction of ovulation. Obstet.
Gynaecol. Reprod. Med. 205–210.
2. Amirikia H, Savoy-Moore RT, Sundareson AS, Moghissi KS. The effects
of long-term androgen treatment on the ovary. Fertil Steril
1986;45:202–8.
3. Bailey CJ. Metformin revisited: its actions and indications for use.
Diabet Med 1988;5:315–20.
4. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and
embryo yields, embryo grade and cell number in IVF. Hum Reprod
2006;21:2845–9.
5. Barad D, Gleicher N. Increased oocyte production after treatment with
dehydroepiandrosterone. Fertil Steril 2005;84:756.
6. Biljan MM, Buckett WM, Dean N, Phillips SJ, Tan SL. The outcome of
IVF-embryo transfer treatment in patients who develop three follicles or
less. Hum Reprod 2000;15:2140–2144.
7. Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl
4):S3–5.
8. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham
G, et al. Postmenopausal dehydroepiandrosterone administration increases
free insulin-like growth factor-I and decreases high-density
lipoprotein: a six-month trial. Fertil Steril 1998;70:107–10.
9. CofflerMS, Patel K, Dahan MH, Yoo RY,Malcom PJ, Chang RJ. Enhanced
granulosa cell responsiveness to follicle-stimulating hormone during
insulin infusion in women with polycystic ovary syndrome treated with
pioglitazone. J Clin Endocrinol Metab 2003;88:5624–31.
10. E. Y. Adashi, C. E. Resnick, A. J. D’Ercole, M. E. Svoboda, and J.
J. Van Wyk, “Insulin-like growth factors as intraovarian regulators of
granulosa cell growth and function.,” Endocrine Reviews, vol. 6, no. 3,
pp. 400–420, 1985.
11. Falbo A, Orio F, Venturella R, Rania E, Materazzo C, Tolino A, et
al. Does metformin affect ovarian morphology in patients with polycystic
ovary syndrome? A retrospective cross-sectional preliminary analysis. J
Ovarian Res 2009;31:2–5.
12. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in
polycystic ovary syndrome. Hum Reprod Update 2008;14:367–78.
13. Fried G, Remaeus K, Harlin J, Krog E, Csemiczky G, Aanesen A, et al.
Inhibin B predicts oocyte number and the ratio IGF-I/IGFBP-1 may
indicate oocyte quality during ovarian hyperstimulation for in vitro
fertilization. J Assist Reprod Genet. 2003;20 (5) :167–76.
14. Gleicher, N., Barad, D.H. Dehydroepiandrosterone (DHEA)
supplementation in diminished ovarian reserve (DOR). Reprod. Biol.
Endocrinol. 2011;9, 67.
15. Gleicher, N., Weghofer, A., Barad, D.H., 2011. The role of androgens
in follicle maturation and ovulation induction: friend or foe of
infertility treatment? Reprod. Biol. Endocrinol. 9, 116.
16. Gleicher, N., Kim, A., Weghofer, A., Kushnir, V.A., Shohat-Tal, A.,
Lazzaroni, E., Lee, H.J., Barad, D.H., 2013. Hypoandrogenism in
association with diminished functional ovarian reserve. Hum. Reprod. 28,
1084–1091.
17. Harper AJ, Buster JE, Casson PR. Changes in adrenocortical function
with aging and therapeutic implications. Semin Reprod Endocrinol
1999;17:327–38.
18. Hillier SG, Whitelaw PF, Smyth CD. Follicular estrogen synthesis:
the ‘2-cell, two-gonadotrophin’ model revisited. Mol Cell Endocrinol
1994;100:5–4.
19. Lin LT, Wang PH, Wen ZH, Li CJ, Chen SN, Tsai EM, et al. The
application of Dehydroepiandrosterone on improving mitochondrial
function and reducing apoptosis of cumulus cells in poor ovarian
responders. Int J Med Sci. 2017;14(6):585–94.
20. Magamage MPS, Zengyo M, Moniruzzaman M, Miyano T. Testosterone
induces activation of porcine primordial follicles in vitro. Reprod Med
Biol. 2011;10(1):21–30.
21. McGee, E.A., Hsueh, A.J., 2000. Initial and cyclic recruitment of
ovarian follicles. Endocr. Rev. 21, 200–214.
22. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of
metformin on spontaneous and clomiphene-induced ovulation in the
polycystic ovary syndrome. N Engl J Med 1998;338:1876–1880.
23.Orvieto R, Meltcer S, Nahum R, Rabinson J, Anteby EY, Ashkenazi J.
The influence of body mass index on in vitro fertilization outcome. Int
J Gynaecol Obstet 2009; 104:53–55.
24. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential
benefits of metformin in the polycystic ovary syndrome: a comprehensive
review. Endocr Rev 2009;30:1–50.
25. Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and
local effects of metformin administration in patients with polycystic
ovary syndrome (PCOS): relationship to the ovulatory response. Hum
Reprod 2010;25:1005–13.
26. Sen A, Prizant H, Light A, Biswas A, Hayes E, Lee HJ, et al.
Androgens regulate ovarian follicular development by increasing follicle
stimulating hormone receptor and microRNA-125b expression. Proc Natl
Acad Sci U S A. 2014;111(8):3008–13.
27. Smith P, Steckler TL, Veiga-Lopez A, Padmanabhan V. Developmental
programming: differential effects of prenatal testosterone and
dihydrotestosterone on follicular recruitment, depletion of follicular
reserve, and ovarian morphology in sheep. Biol Reprod.
2009;80(4):726–36.
28. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck DJ. Metformin
therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin
resistance, hyperandrogenemia, and systolic blood pressure, while
facilitating normal menses and pregnancy. Metabolism 1994;43: 647–54.
29. X.-C. Jia, J. Kalmijn, and A. J. W. Hsueh, “Growth hormone enhances
follicle
Stimulating hormone induced differentiation of cultured rat granulosa
cells,” Endocrinology, vol. 118, no. 4, pp. 1401–1409, 1986.